John Reckless
Consultant Physician & Endocrinologist
1. Personal specific pecuniary or personal family interest:DOI from 02/10/06
Personal Specific
  1. British cardiac Society invited debate “Cardiologists are excused of practising ‘tick-box’ medicine to the detriment of their patients (Honorarium and travel expenses) Astra Zeneca.
  2. Trustee (chairman until July 2005) HEART UK, the cholesterol Charity Heart UK
  3. Member, Joint British Societies – working group, producing the JBS2 CVD prevention guidelines published in HEART, Dec 2005. HEART UK, JBS2 committee.
DOI from 14/03/07
  1. Trustee (chairman until July 2005) Heart UK, the cholesterol charity Heart UK
  2. Member, Joint British Societies - working group, producing the JBS2 CVD prevention guidelines, published in HEART Dec 2005
Industry Organisation: HEART UK, HEART UK, JBS2committee.
2. Personal non-specific pecuniary interest:DOI from 02/10/06
  1. Diabetes Advisory Board 2006-7 (Incretin-related)
  2. Ezetimibe Advisory Board 2005-07
  3. Torce trapib Advisory Board 2005–2006 (also investigator) - (Torcetrapib withdrawn November 2006)
  4. Omacor Advisory Board Last 2005
  5. Diabetes advisory board (field outcomes) [last 2005]
  6. Obesity advisory board (rimonabant) 2005–2006 [also investigator]
  7. Diabetes advisory board (pioglitazone) 2004–2006 [also investigator]
  8. Chair IDMC (independent data monitoring committee) (agent not LDL cholesterol related & minimum 2–3 years to license submission) - [drug development ceased 2006 due to animal toxicology]
Industry/Organisation
MSD, Schering Plough/MSD, Pfizer, Solvay, Fournier, Sanofi Aventis, Takeda, GSK

DOI from 14/03/07
  1. Diabetes Advisory Board 2006-7 (Incretin-related)
  2. Ezetimibe Advisory Board 2005-07
  3. Torce trapib Advisory Board 2005–2006 (also investigator) - (Torcetrapib withdrawn November 2006)
  4. Omacor Advisory Board Last 2005
  5. Diabetes advisory board (field outcomes) [last 2005]
  6. Obesity advisory board (rimonabant) 2005–2006 [also investigator]
  7. Diabetesadvisory board (pioglitazone) 2004–2006 [also investigator]
  8. Chair IDMC (independent data monitoring committee) (agent not LDL cholesterol related & minimum 2–3 years to license submission) - [drug development ceased 2006 due to animal toxicology]
Industry/Organisation
MSD, Schering Plough/MSD, Pfizer, Solvay, Fournier, Sanofi Aventis, Takeda, GSK
3. Non-personal specific pecuniary interest:DOI from02/10/06

Non Personal Specific
  1. Trustee (chairman until July 2005) Heart UK, the cholesterol charity Heart UK
  2. Member, Joint British Societies - working group, producing the JBS2 CVD prevention guidelines, published in HEART Dec 2005 HEART UK, JBS2 committee
  3. Department of endocrinology, Diabetes and Metabolism research lead, Royal United Hospital, Bath – Acted as the main supervisor of research staff, and as local principle investigator or investigator for research studies in the department. All four consultants are investigators on studies in order to comply with GCP/ICSH, and for emergency consultant cover for the studies. Studies are in the CVD, diabetes, hypertension, endocrine and metabolism areas, and mat involve lipid related studies of relevance to NICE GDG Lipids one study over the last 2–3 year, drawing to a close, has some limited relevance. This is the addition of ezetimibe to existing statin, or doubling existing statin dose, in post myocardial infarction/acute coronary syndrome.
4. Non-personal non-specific pecuniary interest:DOI From 02/10/06
  1. Part contribution to purchase of departmentl Body Composition Analyser (obesity related) 2006. - Pfizer
DOI from 14/03/07
  1. Part contribution to purchase of departmentl Body Composition Analyser (obesity related) 2006. - Pfizer
5. Personal non-pecuniaryNone

From: Appendix L, Declarations of Interest – Lipid Modification Guideline Development Group

Cover of Lipid Modification
Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease [Internet].
NICE Clinical Guidelines, No. 67.
National Collaborating Centre for Primary Care (UK).
Copyright © 2008, Royal College of General Practitioners.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce anypart of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.